ChiCTR2500098055 版本V1.0 版本创建时间2025/02/28 17:58:47 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500098055 

最近更新日期:

Date of Last Refreshed on:

2025-02-28 17:58:39 

注册时间:

Date of Registration:

2025-02-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于长程心电监测的社区亚临床房颤筛查与综合管理策略研究: 一项随机临床试验

Public title:

Community-based Subclinical Atrial Fibrillation Screening and Comprehensive Management Strategy Based on Long-term Electrocardiogram Monitoring: A Randomized Clinical Trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于长程心电监测的社区亚临床房颤筛查与综合管理策略研究: 一项随机临床试验

Scientific title:

Community-based Subclinical Atrial Fibrillation Screening and Comprehensive Management Strategy Based on Long-term Electrocardiogram Monitoring: A Randomized Clinical Trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周欣 

研究负责人:

杨清 

Applicant:

Zhou Xin 

Study leader:

Yang Qing 

申请注册联系人电话:

Applicant telephone:

+86 186 2257 5041

研究负责人电话:

Study leader's
telephone:

+86 139 1171 1189

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xinzhou@tmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

cardio-yq@tmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

天津市和平区鞍山道154号

研究负责人通讯地址:

天津市和平区鞍山道154号

Applicant address:

154, Anshan Road, Heping District, Tianjin, China

Study leader's address:

154, Anshan Road, Heping District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津医科大学总医院

Applicant's institution:

Tianjin Medical University General Hospital

研究负责人所在单位:

天津医科大学总医院

Affiliation of the Leader:

Tianjin Medical University General Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

IRB2025-YX-042-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

天津医科大学总医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Tianjin Medical University General Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-01-23 00:00:00

伦理委员会联系人:

金东来

Contact Name of the ethic committee:

Jin Donglai

伦理委员会联系地址:

天津市和平区鞍山道154号

Contact Address of the ethic committee:

154, Anshan Road, Heping District, Tianjin, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 60362779

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津医科大学总医院

Primary sponsor:

Tianjin Medical University General Hospital

研究实施负责(组长)单位地址:

天津市和平区鞍山道154号

Primary sponsor's address:

154, Anshan Road, Heping District, Tianjin, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学总医院

具体地址:

天津市和平区鞍山道154号

Institution
hospital:

Tianjin Medical University General Hospital

Address:

154, Anshan Road, Heping District, Tianjin, China

经费或物资来源:

天津医科大学总医院临床研究项目

Source(s) of funding:

Tianjin Medical University General Hospital Clinical Research Project

研究疾病:

亚临床心房颤动  

Target disease:

Subclinical Atrial Fibrillation

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.2025年完成社区5000名亚临床房颤高危老人的长程心电监测的筛查工作,获取真实世界中高危老年人群中亚临床房颤的检出率。 2.通过随机对照试验设计,结合社区体检和长程心电监测数据,比较个体化的房颤综合管理策略(房颤临床)和常规管理对预防房颤及卒中/TIA发生风险的效果。 3.形成一套针对社区高危亚临床房颤患者的特殊防、筛、诊、治、康综合管理策略。  

Objectives of Study:

1.Complete the screening of 5,000 community-dwelling elderly individuals at high risk for subclinical atrial fibrillation through long-term electrocardiogram monitoring by 2025, in order to obtain the detection rate of subclinical atrial fibrillation in high-risk elderly populations in the real world. 2.Design a randomized controlled trial to compare the effectiveness of an individualized atrial fibrillation comprehensive management strategy versus conventional management in preventing atrial fibrillation and reducing the risk of stroke/TIA, using data from community health checkups and long-term electrocardiogram monitoring. 3.Develop a comprehensive management strategy for special prevention, screening, diagnosis, treatment, and rehabilitation for community-dwelling high-risk subclinical atrial fibrillation patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

年龄>75岁,或年龄>65岁且CHA2DS2-VASc评分大于3分

Inclusion criteria

Age>75 years, or age>65 years with a CHA2DS2-VASc score greater than 3

排除标准:

1.当前或既往有房颤、房扑或房性心动过速的诊断; 2.正在接受长期抗凝治疗; 3.接受临终关怀; 4.终末期肾病; 5.诊断为中度或更严重的痴呆; 6.已植入心脏起搏器和/或除颤器; 7.有过敏历史(如对贴片胶黏剂过敏); 8.已知有转移性癌症。

Exclusion criteria:

1.Current or past diagnosis of atrial fibrillation, atrial flutter, or atrial tachycardia; 2.Currently receiving long-term anticoagulant therapy; 3.Receiving hospice care; 4.End-stage renal disease; 5.Diagnosed with moderate or more severe dementia; 6.Have an implanted pacemaker and/or defibrillator; 7.History of allergies (e.g., adhesive allergy to patches); 8.Known metastatic cancer.

研究实施时间:

Study execute time:

From 2025-04-01 00:00:00 To 2028-03-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-04-01 00:00:00 To 2026-03-31 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

100

Group:

Intervention group

Sample size:

干预措施:

进一步的强化长时程筛查、危险因素管理以及专科指导的抗凝和节律控制治疗

干预措施代码:

Intervention:

Further strengthening of long-term screening, management of risk factors, and anticoagulation and rhythm control therapy under specialist guidance

Intervention code:

组别:

对照组

样本量:

100

Group:

Control group

Sample size:

干预措施:

该组患者仅进行社区常规管理

干预措施代码:

Intervention:

Patients in this group only received routine community management

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学总医院 

单位级别:

三级 

Institution
hospital:

Tianjin Medical University General Hospital

Level of the institution:

Tertiary

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市和平区南营门街社区卫生服务中心 

单位级别:

社区卫生服务中心 

Institution
hospital:

Community Health Service Center, Nanyingmen Subdistrict, Heping District, Tianjin

Level of the institution:

Community Health Service Center

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市和平区小白楼街社区卫生服务中心 

单位级别:

社区卫生服务中心 

Institution
hospital:

Community Health Service Center, Xiaobailou Subdistrict, Heping District, Tianjin

Level of the institution:

Community Health Service Center

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市和平区劝业场街社区卫生服务中心 

单位级别:

社区卫生服务中心 

Institution
hospital:

Community Health Service Center, Quanyechang Subdistrict, Heping District, Tianjin

Level of the institution:

Community Health Service Center

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市和平区新兴街社区卫生服务中心 

单位级别:

社区卫生服务中心 

Institution
hospital:

Community Health Service Center, Xinxing Subdistrict, Heping District, Tianjin

Level of the institution:

Community Health Service Center

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市和平区五大道街社区卫生服务中心 

单位级别:

社区卫生服务中心 

Institution
hospital:

Community Health Service Center, Wudadao Subdistrict, Heping District, Tianjin

Level of the institution:

Community Health Service Center

测量指标:

Outcomes:

指标中文名:

心房颤动

指标类型:

主要指标

Outcome:

Atrial fibrillation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑卒中/短暂性脑缺血发作

指标类型:

次要指标

Outcome:

Stroke/Transient Ischemic Attack (TIA)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抗凝治疗率

指标类型:

次要指标

Outcome:

Anticoagulation therapy rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

全因死亡

指标类型:

次要指标

Outcome:

All-cause mortality

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

主要不良心血管事件

指标类型:

次要指标

Outcome:

Major adverse cardiovascular events

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

大出血

指标类型:

次要指标

Outcome:

Major bleeding

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

新诊断的痴呆

指标类型:

次要指标

Outcome:

New onset dementia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机化由研究者采用EDC中央随机化系统进行分层随机,保证干预组和对照组在性别、年龄、基础疾病等方面的均衡。

Randomization Procedure (please state who generates the random number sequence and by what method):

The randomization was stratified using the EDC central randomization system by the researchers to ensure a balance between the intervention group and the control group in terms of gender, age, underlying diseases, and other factors.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not shared

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子健康记录(包括社区卫生服务中心记录)、住院病例统计(HES)、天津市疾控中心(CDC)数据登记

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic health records (including records from community health service centers), hospital episode statistics (HES), and data registration from the Tianjin Center for Disease Control and Prevention (CDC)

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-02-28 17:58:39